HUTCHMED CHINA-ADR (HCM) Stock News

NASDAQ:HCM - Nasdaq - US44842L1035 - ADR - Currency: USD

16.45 +0.58 (+3.65%)

After market: 16.45 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

HCM Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Reports 2025 Interim Results

11 days ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

2 months ago - By: HUTCHMED (China) Limited

HUTCHMED to Announce 2025 Half-Year Financial Results

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED to Announce 2025 Half-Year Financial Results

2 months ago - By: HUTCHMED (China) Limited

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

2 months ago - By: Zacks Investment Research

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

2 months ago - By: HUTCHMED (China) Limited

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

3 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

3 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

3 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

3 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

3 months ago - By: Virtual Investor Conferences - Mentions: VIOT LSE - NYSE ...

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

3 months ago - By: Virtual Investor Conferences - Mentions: YRD IH BLTE VIOT ...

UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

3 months ago - By: Virtual Investor Conferences - Mentions: YRD IH BLTE VIOT ...

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

4 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

4 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

4 months ago - By: HUTCHMED (China) Limited

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

4 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

5 months ago - By: Benzinga - Mentions: PRGS PVH CRWV MVST ...

Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

5 months ago - By: HUTCHMED (China) Limited

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

6 months ago - By: HUTCHMED (China) Limited

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

6 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee